Comparative Pharmacology
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus ROCEPHIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus ROCEPHIN.
CEFTAROLINE FOSAMIL vs ROCEPHIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with peptidoglycan cross-linking and leading to cell lysis.
600 mg IV every 12 hours infused over 1 hour
1-2 g IV or IM every 24 hours; maximum 4 g/day for serious infections.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Terminal half-life ~6-8 hours in adults with normal renal function; prolonged to 12-24 hours in neonates and elderly.
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Renal (33-67%) and biliary (40-50%); primarily excreted unchanged. Dual elimination: ~50% renal, ~50% biliary/fecal.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic